Claims for Patent: 9,730,888

Summary for Patent: 9,730,888

Title:	Method of enhancing delivery of therapeutic compounds to the eye
Abstract:	The invention provides methods for enhancing the delivery of therapeutic compounds to the eye of a subject by administering plasmin or derivatives thereof and the therapeutic compounds to the eye.
Inventor(s):	Pan; Zhuo-Hua (Troy, MI), Ivanova; Elena (White Plains, NY)
Assignee:	Wayne State University (Detroit, MI)
Application Number:	14/777,420
Patent Claims:	1. A method of enhancing the delivery of a therapeutic agent to an eye of a subject comprising administering, by intravitreous injection, a plasmin or derivative thereof and the therapeutic agent to the eye, wherein the therapeutic agent comprises a nucleic acid expression vector. 2. The method of claim 1, wherein the plasmin or derivative thereof is a miniplasmin or a microplasmin (ocriplasmin). 3. The method of claim 1, wherein nucleic acid expression vector is a viral vector comprising a transgene. 4. The method of claim 3, wherein the transgene is an opsin. 5. The method of claim 4, wherein the opsin is selected from the group consisting of channelrhodopsin, halorhodopsin, melanopsin, pineal opsin, bacteriorhodopsin, and proteorhodopsin, or a functional variant thereof. 6. The method of claim 3, wherein said transgene is operably linked to a cell-specific promoter. 7. The method of any one of the preceding claims, wherein the therapeutic agent is encapsulated in a nanoparticle, a polymer, or a liposome. 8. The method of claim 1, wherein the subject is suffering from an ocular disease or disorder. 9. The method of claim 1, wherein the plasmin or derivative thereof and the therapeutic agent are delivered concurrently or sequentially. 10. The method of claim 1, wherein the therapeutic agent is delivered to a retinal cell. 11. The method of claim 10, wherein the retinal cell is a retinal ganglion cell, a retinal bipolar cell, a retinal horizontal cell, an amacrine cell, a photoreceptor cell, a Muller glial cell, or a retinal pigment epithelial cell. 12. A method of increasing light sensitivity or improving or restoring vision in a subject comprising administering a plasmin or derivative thereof and a nucleic acid expression vector that encodes an opsin to the vitreous of the eye. 13. The method of claim 12, wherein said opsin is selected from the group consisting of channelrhodopsin, halorhodopsin, melanopsin, pineal opsin, bacteriorhodopsin, and proteorhodopsin, or a functional variant thereof. 14. The method of claim 12 or 13, wherein the subject has an ocular disease or disorder. 15. The method of claim 12, wherein the plasmin or derivative thereof is a miniplasmin or a microplasmin (ocriplasmin). 16. The method of claim 12, wherein said opsin is operably linked to a cell-specific promoter. 17. The method of claim 12, wherein the plasmin or derivative thereof and the nucleic acid expression vector are delivered concurrently or sequentially. 18. The method of claim 12, wherein the nucleic acid expression vector is delivered to a retinal cell. 19. The method of claim 18, wherein the retinal cell is a retinal ganglion cell, a retinal bipolar cell, a retinal horizontal cell, an amacrine cell, a photoreceptor cell, a Muller glial cell, or a retinal pigment epithelial cell. 20. The method of claim 12, wherein the nucleic acid expression vector is a viral vector.

Details for Patent 9,730,888

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422	02/22/2017		2033-03-14
Thrombogenics Inc.	JETREA	ocriplasmin	Injection	125422	10/17/2012		2033-03-14